Opinion|Videos|October 7, 2024
Innovations in NMIBC Treatment: The Synergy of BCG and PD-1/PD-L1 Inhibitors
Key Takeaways
- Combining BCG and PD-1/PD-L1 inhibitors may enhance antitumor activity through complementary mechanisms, potentially improving outcomes in NMIBC.
- BCG stimulates immune response, while PD-1/PD-L1 inhibitors prevent immune evasion, providing a rationale for their combined use.
Panelists discuss how combining BCG with PD-1/PD-L1 inhibitors may enhance antitumor activity compared with using each agent alone, emphasizing the rationale for this combination therapy and its potential to evolve treatment strategies for non–muscle-invasive bladder cancer (NMIBC) while also considering the implications for patient flow in urology practice and the necessity of a multidisciplinary approach.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- How might the combination of BCG and PD-1/PD-L1 inhibitors affect antitumor activity compared with using each agent alone?
- What is the rationale for using these therapies in combination?
- How do you think the combination therapies will evolve treatment of non–muscle-invasive bladder cancer (NMIBC)?
- How would the use of PD-1/PD-L1 inhibitors plus BCG in high-risk NMIBC impact patient flow in urology practice?
THE SPEAKER WILL HIGHLIGHT THE IMPORTANCE OF A MULTIDISCIPLINARY APPROACH
Advertisement
Related to this article
Robert J. Motzer, MD, discusses the significance of the belzutifan plus lenvatinib approval, adverse event management with the combination, and the evolving role of HIF-2α inhibition in ccRCC.
Brian Mazzarella, MD, discusses the landscape for intermediate-risk prostate cancer and early VAPOR 2 findings on water vapor ablation.
The phase 3 BiPASS trial is evaluating the use of 68Ga-PSMA-PET in combination with MRI for pre-biopsy prostate cancer detection.
In RTOG 3506, adding enzalutamide to standard ADT and salvage radiotherapy was associated with 2-year PFS benefit.
Armine K. Smith, MD, discusses the importance of integrating sexual health into bladder cancer care, including proactive counseling, preservation strategies, and multidisciplinary support.
In the phase 3 PACE-A trial, SBRT and prostatectomy showed similar 8-year disease control in localized prostate cancer, with lower rates of urinary incontinence after SBRT.
Using PSMA-PET imaging and genomic testing to obtain better information earlier in the disease course changes what clinicians can do with diagnosis and treatment planning.
The registrational study is designed to evaluate the diagnostic performance of 68Ga-DOTA-RM2 vs histopathology in prostate cancer.
Advertisement
Advertisement
Trending on Urology Times
1
FDA grants fast track designation to pre-biopsy 68Ga-PSMA-PET program
2
Enzalutamide plus salvage radiotherapy associated with improved PFS in high-risk BCR
3
Brian Mazzarella, MD, reviews early data on water vapor therapy for localized prostate cancer
4
Pivotal trial launches of GRPR-targeted PET imaging agent in prostate cancer
5